ARTICLE | Company News
ImmunoPharmaceutics Inc. other research news
March 14, 1994 8:00 AM UTC
ImmunoPharmaceutics received a $75,000 Phase I SBIR from the National Institute of General Medical Science to convert antibodies or other bioactive proteins into small-molecule, non-peptide, orally active antagonists of human neutrophil elastase (HNE). ...